TAILIEUCHUNG - Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: A real-world, patient-level analysis

It has been postulated that patient’s sex impacts response to immunotherapy. Sex modulation of immunotherapy benefit, however, has not yet been explored using patient-level data, where potential confounder, as well as histologic type, can be accounted for. Here we investigated the association between sex and chemoimmunotherapy efficacy for non-small cell lung cancer (NSCLC) using a large, nation-wide dataset. | Tuminello et al. BMC Cancer 2022 22 80 https s12885-022-09187-y RESEARCH Open Access Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology a real-world patient-level analysis Stephanie Tuminello1 2 Naomi Alpert1 Rajwanth R. Veluswamy1 3 4 Arvind Kumar4 Jorge E. Gomez4 Raja Flores5 and Emanuela Taioli1 4 6 Abstract Background It has been postulated that patient s sex impacts response to immunotherapy. Sex modulation of immunotherapy benefit however has not yet been explored using patient-level data where potential confounders as well as histologic type can be accounted for. Here we investigated the association between sex and chemoimmu- notherapy efficacy for non-small cell lung cancer NSCLC using a large nation-wide dataset. Patients amp methods Stage IV NSCLC patients diagnosed in 2015 were identified in the National Cancer Database NCDB . Patients were treated with either chemoimmunotherapy or chemotherapy alone. The efficacy of the addition of immunotherapy treatment by sex was investigated using both an adjusted Cox proportional hazards model and propensity-score matching in both the overall cohort and stratified by histological subtype. Results 2064 16 patients received chemoimmunotherapy and10 733 84 received chemotherapy alone. Adjusted survival analysis in the overall cohort showed that both males hazards ratio HR adj 95 CI and females HRadj 95 CI had better OS when treated with chemoimmunotherapy than chemo- therapy alone with no statistically significant interaction between sex and receipt of immunotherapy p . Propensity matching confirmed these results. However for those with squamous cell histology male patients derived more benefit from chemoimmunotherapy treatment than females HRadj 95 CI vs HRadj 95 CI p for interaction . Conclusion Male patients with squamous cell carcinoma may derive more benefit from chemoimmunotherapy .

• Y khoa - Dược
• BMC Cancer
• Immune checkpoint inhibitors
• Squamous cell carcinoma
• Nation wide dataset
• Chemoimmunotherapy efficacy
• Non small cell lung cancer
• Cancer patient pathways
• Colorectal cancer
• Lung cancer
• Breast cancer
• Prostate cancer
• Ovarian cancer
• Cancer detection
• Ovarian cancer symptoms
• Ovarian cancer signs
• Ovarian cancer tests
• Cancer biomarkers
• Pediatric cancer
• Familial cancer predisposition
• Hereditary cancer syndrome
• Genetic cancer susceptibility
• Advanced cancer
• Biliary tract cancer
• Multimodal intervention
• Pancreatic cancer
• Physical activity
• Breast cancer screening
• Familial breast cancer
• Young breast cancer survivors
• High risk relatives
• Randomized trial
• Childhood cancer
• Childhood cancer survivor
• Thyroid cancer screening
• Secondary cancer
• Cancer screening
• Community awareness
• Cancer education
• Cervical cancer
• Prior cancer
• Cancer survivors
• Cancer registry
• Second cancer
• Surgical oncology
• Cancer imaging
• Radiation oncologists
• Medical oncologists
• Oesophagogastric cancer
• Liver cancer
• Hepatobiliary cancer
• Multidisciplinary rehabilitation
• EGFR mutation
• Family history of cancer
• Inherited susceptibility
• Cancer predisposition genes
• Lung cancer aetiology
• Cancer stem cells
• Oct4 overexpressing lung cancer
• Human lung cancer xenograft model
• Disease free survivals
• Cancer hallmarks
• Cancer genesis
• Defiant disease
• Mutational signature
• Cancer diagnosis
• Cancer genomics
• Molecular medicine
• Whole genome sequencing
• Cancer susceptibility gene
• Breast cancer prognosis
• Next generation sequencing
• Quality of care
• Quality indicators
• Shifting cancer care
• German cancer society
• Colorectal cancer screening
• Stomach cancer screening
• Lung cancer survivor
• Physician recommendation
• Total number of lymph nodes
• Lymph node ratio
• Left colon cancer
• Right colon cancer
• Overall survival
• Cumulative incidence
• Esophageal cancer
• Head and neck cancer
• Metachronous cancer
• Young onset
• Reproductive cancer
• Risk factor
• Early detection of cancer
• Gastric cancer incidence
• Population based specialized registry
• Gastric cancer survival
• Gastric cancer clinical characteristics
• Gastric cancer pathological characteristics
• Lung Cancer Screening
• Racial disparities
• Lung Cancer diagnosis
• Screening adherence
• Second primary colorectal cancer
• Standardized incidence ratio
• Left sided colon cancer
• Right sided colon cancer
• Quality of cancer care
• Population based study